Famygen Life Sci Drug Patent Portfolio

Famygen Life Sci owns 1 orange book drug protected by 6 US patents Given below is the list of Famygen Life Sci's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11400077 Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders 25 Oct, 2039
Active
US10278918 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
Active
US10772829 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
Active
US11090261 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
Active
US11844858 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
Active
US9795560 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
Active


Given below is the list of recent legal activities going on the following drug patents of Famygen Life Sci.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 15 Mar, 2024 US10772829
Electronic Review 02 Feb, 2024 US11844858
Email Notification 20 Dec, 2023 US11844858
Patent Issue Date Used in PTA Calculation 19 Dec, 2023 US11844858
Recordation of Patent Grant Mailed 19 Dec, 2023 US11844858
Recordation of Patent eGrant 19 Dec, 2023 US11844858
Patent eGrant Notification 19 Dec, 2023 US11844858
Mail Patent eGrant Notification 19 Dec, 2023 US11844858
Email Notification 30 Nov, 2023 US11844858
Issue Notification Mailed 29 Nov, 2023 US11844858
Dispatch to FDC 15 Nov, 2023 US11844858
Application Is Considered Ready for Issue 15 Nov, 2023 US11844858
Issue Fee Payment Verified 08 Nov, 2023 US11844858
Issue Fee Payment Received 08 Nov, 2023 US11844858
Email Notification 09 Aug, 2023 US11844858


Famygen Life Sci's Family Patents


Family Patents



Famygen Life Sci Drug List

Given below is the complete list of Famygen Life Sci's drugs and the patents protecting them.


1. Ryzumvi

Ryzumvi is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11400077 Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders 25 Oct, 2039
(15 years from now)
Active
US10278918 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
(9 years from now)
Active
US10772829 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
(9 years from now)
Active
US11090261 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
(9 years from now)
Active
US11844858 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
(9 years from now)
Active
US9795560 Aqueous ophthalmic solutions of phentolamine and medical uses thereof 31 Jan, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ryzumvi's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List